Light-Emitting Diode-Generated Red Light Inhibits Keloid Fibroblast Proliferation

被引:21
作者
Mamalis, Andrew [1 ,2 ]
Jagdeo, Jared [1 ,2 ,3 ]
机构
[1] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA
[2] Sacramento VA Med Ctr, Dermatol Serv, Mather, CA USA
[3] Suny Downstate Med Ctr, Dept Dermatol, Brooklyn, NY 11203 USA
关键词
CLINICAL SURVEY; VISIBLE-LIGHT; SKIN; MODEL; THERAPY; PREVALENCE; TAIWAN; SCARS; ACNE;
D O I
10.1097/01.DSS.0000452650.06765.51
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND Red light is part of the visible light spectrum that does not generate DNA adducts associated with skin cancer and photoaging and may represent a safer therapeutic modality for treatment of keloid scars and other fibrotic skin diseases. Our laboratory previously demonstrated that light-emitting diode-generated red light (LED-RL) inhibits proliferation of skin fibroblasts. The effects of LED-RL on keloidal skin are not well characterized. OBJECTIVE To determine the effect of LED-RL on keloid-derived fibroblast proliferation and viability in vitro. METHODS Irradiation of primary keloid-derived human skin fibroblasts using LED-RL panels was performed in vitro, and modulation of proliferation and viability was quantified using trypan blue dye exclusion assay. Statistical analysis was performed using analysis of variance to compare treatment arms and the Student t-test to compare each treatment arm with the paired bench control arm. RESULTS Keloid fibroblasts treated with LED-RL 240, 320, and 480 J/cm(2) demonstrated statistically significant dose-dependent decreases in relative proliferation rate of 12.4%, 16.5%, and 28.9%, respectively, compared with matched nonirradiated controls (p < .05) and did not significantly alter viability relative to the matched nonirradiated controls. CONCLUSION Light-emitting diode-generated red light can inhibit keloid fibroblast proliferation in a dose-dependent manner without altering viability. Light-emitting diode-generated red light has the potential to contribute to the treatment of keloids and other fibrotic skin diseases and is worthy of further translational and clinical investigation.
引用
收藏
页码:35 / 39
页数:5
相关论文
共 25 条
[21]  
Uitto Jouni, 2008, J Drugs Dermatol, V7, ps12
[22]   Development, Validation, and Testing of a Human Tissue Engineered Hypertrophic Scar Model [J].
van den Broek, Leonarda J. ;
Niessen, Frank B. ;
Scheper, Rik J. ;
Gibbs, Susan .
ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2012, 29 (04) :389-402
[23]   FK506 inhibits the enhancing effects of transforming growth factor (TGF)-β1 on collagen expression and TGF-β/Smad signalling in keloid fibroblasts: implication for new therapeutic approach [J].
Wu, C-S ;
Wu, P-H ;
Fang, A-H ;
Lan, C-C E. .
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) :532-541
[24]   An Ex Vivo Model Employing Keloid-Derived Cell-Seeded Collagen Sponges for Therapy Development [J].
Yagi, Yosuke ;
Muroga, Eri ;
Naitoh, Motoko ;
Isogai, Zenzo ;
Matsui, Seiya ;
Ikehara, Susumu ;
Suzuki, Shigehiko ;
Miyachi, Yoshiki ;
Utani, Atsushi .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (02) :386-393
[25]   Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey [J].
Yang, Y-C ;
Cheng, Y-W ;
Lai, C-S ;
Chen, W. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 (05) :643-649